Allarity Therapeutics, Inc.
ALLR · Nasdaq · United States
Share price · ALLR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALLR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Nov 2026+15.6%
- 2 Nov 2026+12.3%
- 16 Oct 2026+7.5%
Nothing announced by ALLR that day or the session before.
- 12 Oct 2026-13.1%
Nothing announced by ALLR that day or the session before.
- 30 Sep 2026+8.8%
- 22 Sep 2026-5.1%
Nothing announced by ALLR that day or the session before.
- 8 Sep 2026-12.0%
Nothing announced by ALLR that day or the session before.
- 5 May 2026+12.0%
Nothing announced by ALLR that day or the session before.
- 21 Apr 2026+10.4%
Nothing announced by ALLR that day or the session before.
- 10 Apr 2026+10.4%
Nothing announced by ALLR that day or the session before.
Share of unusual movement by asset
For each asset, the share of ALLR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | PARP1/2 · Tankyrase 1/2Small molecule | Ovarian Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
March 2027 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | <$0.1M | $4.2M | — | $6.2M-$2.9M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $1.4M | $27M | $3.4M-$2.6M operating cash flow | report ↗ |
| 2026-Q1 | <$0.1M | $1.3M | $30M | $2.8M-$4.5M operating cash flow | report ↗ |
| 2025-Q3 | — | $1.2M | $17M | $2.8M-$3.4M operating cash flow | report ↗ |
| 2025-Q2 | — | $2.3M | $18M | $2.3M-$5.5M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $1.4M | $28M | $2.7M-$2.7M operating cash flow | report ↗ |
| 2024-Q3 | — | $1.0M | $19M | $12M-$5.4M operating cash flow | report ↗ |
| 2024-Q2 | — | $1.1M | $19M | $1.6M-$7.2M operating cash flow | report ↗ |
| 2024-Q1 | — | $2.2M | — | $3.8M-$1.5M operating cash flow | report ↗ |
| 2023-Q3 | — | $1.9M | — | $4.5M-$5.4M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.1M | $0.4M | $2.4M-$2.5M operating cash flow | report ↗ |
| 2023-Q1 | — | $1.4M | $0.3M | $3.4M-$3.2M operating cash flow | report ↗ |
| 2022-Q3 | — | $3.0M | $4.0M | $5.0M-$4.4M operating cash flow | report ↗ |
| 2022-Q2 | — | $1.7M | $7.7M | $5.1M-$4.2M operating cash flow | report ↗ |
| 2022-Q1 | — | $1.3M | $15M | $3.1M-$5.8M operating cash flow | report ↗ |
| 2021-Q3 | — | $1.6M | $5.6M | $1.4M-$2.9M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0.3M | $6.6M | $15M | $2.8M-$15M operating cash flow | report ↗ |
For FY2025, Allarity Therapeutics reported revenue of $0.32M (2024: $0M), R&D spend of $6.6M, up 8.2% YoY, and cash and equivalents of $14.7M. The company recorded a net loss of $11.23M and reported a quarterly net burn of $11.23M.
Allarity remains focused on stenoparib and its DRP companion diagnostic. A new clinical protocol in platinum-resistant ovarian cancer began enrollment in June 2025, and a randomized stenoparib-plus-temozolomide trial in relapsed small cell lung cancer opened in January 2026 with funding from the U.S. Department of Veterans Affairs. The reported revenue came from laboratory service agreements, and other legacy product candidates were terminated.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-30 | Graff Jeremy R. · See Remarks | Option exercise | 39,494 | — | — | Form 4 |
| 2026-09-30 | Graff Jeremy R. · See Remarks | Tax withholding | 14,613 | $0.97 | $14K | Form 4 |
| 2026-09-30 | Graff Jeremy R. · See Remarks | Option exercise (derivative) | 39,494 | — | — | Form 4 |
| 2026-01-28 | Jensen Thomas · CEO | Award / grant | 200,000 | — | — | Form 4 |
| 2026-01-28 | McLaughlin Gerald W. · director | Award / grant | 45,000 | — | — | Form 4 |
| 2026-01-28 | Ervin Jeffrey S · CFO | Award / grant | 150,000 | — | — | Form 4 |
| 2026-01-28 | Graff Jeremy R. · See Remarks | Award / grant | 133,333 | — | — | Form 4 |
| 2026-01-22 | Graff Jeremy R. · See Remarks | Option exercise | 48,147 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 14 reporting institutions held 1.0M shares ($1.0M, 6.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 228,084 | $249K |
| 2 | GEODE CAPITAL MANAGEMENT, LLC | 190,393 | $208K |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 171,795 | $187K |
| 4 | STATE STREET CORP | 137,600 | $150K |
| 5 | VANGUARD FIDUCIARY TRUST CO | 74,913 | $82K |
| 6 | NORTHERN TRUST CORP | 48,103 | $52K |
| 7 | XTX Topco Ltd | 28,967 | $32K |
| 8 | TWO SIGMA INVESTMENTS, LP | 27,492 | $30K |
| 9 | UBS Group AG | 23,158 | $25K |
| 10 | TWO SIGMA SECURITIES, LLC | 12,334 | $13K |
| 11 | CITIGROUP INC | 7,766 | $8K |
| 12 | JONES FINANCIAL COMPANIES LLLP | 1 | $1 |
| 13 | DANSKE BANK A/S | 1 | $1 |
| 14 | Caitong International Asset Management Co., Ltd | 1 | $1 |